179 related articles for article (PubMed ID: 36172110)
1. The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study.
Tian C; Yang J; Xie N; Tang Y; Zhou H; Hu ZY; Ouyang Q
Ann Transl Med; 2022 Sep; 10(17):924. PubMed ID: 36172110
[TBL] [Abstract][Full Text] [Related]
2. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
5. Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer.
Knudsen AM; Modvig MW; Vogsen M; Kodahl AR
Med Oncol; 2024 Mar; 41(5):99. PubMed ID: 38538985
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
[TBL] [Abstract][Full Text] [Related]
7. First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients.
Liang X; Yan Y; Wang L; Song G; DI L; Jiang H; Wang C; Li H
Oncol Lett; 2015 Feb; 9(2):987-993. PubMed ID: 25621076
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin M; Zielinski C; Ruiz-Borrego M; Carrasco E; Turner N; Ciruelos EM; Muñoz M; Bermejo B; Margeli M; Anton A; Kahan Z; Csöszi T; Casas MI; Murillo L; Morales S; Alba E; Gal-Yam E; Guerrero-Zotano A; Calvo L; de la Haba-Rodriguez J; Ramos M; Alvarez I; Garcia-Palomo A; Huang Bartlett C; Koehler M; Caballero R; Corsaro M; Huang X; Garcia-Sáenz JA; Chacón JI; Swift C; Thallinger C; Gil-Gil M
Ann Oncol; 2021 Apr; 32(4):488-499. PubMed ID: 33385521
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
14. Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies.
Guan X; Ma F; Li Q; Chen S; Lan B; Fan Y; Wang J; Luo Y; Cai R; Zhang P; Li Q; Xu B
Biomark Res; 2023 Feb; 11(1):21. PubMed ID: 36803645
[TBL] [Abstract][Full Text] [Related]
15. Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
Li Y; Gong C; Lu Q; Zhou Z; Luo T; Li W; Li G; Ge R; Xu F; Wang B
Front Oncol; 2020; 10():271. PubMed ID: 32195186
[No Abstract] [Full Text] [Related]
16. Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients -A retrospective study.
Liu Q; Qiu J; Lu Q; Ma Y; Fang S; Bu B; Song L
Front Oncol; 2022; 12():873570. PubMed ID: 35957911
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study.
Gui X; Li H; Yan Y; Zhang R
Oncol Lett; 2020 Dec; 20(6):378. PubMed ID: 33154776
[TBL] [Abstract][Full Text] [Related]
18. The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine.
Zhu Y; Li K; Zhang J; Wang L; Sheng L; Yan L
Transl Cancer Res; 2021 Mar; 10(3):1193-1203. PubMed ID: 35116447
[TBL] [Abstract][Full Text] [Related]
19. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V;
Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
